Want to see AU:HMD full AI Analyst Report?
Top Page
HeraMED Ltd.
(Sydney:HMD)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$0.03
▼(-15.00% Downside)
Action:Reiterated
Date:06/04/26
The score is held down primarily by persistent losses and recurring negative operating/free cash flow (cash burn), alongside recent revenue contraction. A debt-free balance sheet with improved gross margin provides some support, but technical indicators remain weak-to-mixed and valuation signals are constrained by negative earnings and no dividend data.
Positive Factors
Debt-free balance sheet
Eliminating debt reduces interest and refinancing exposure and gives the business more financial flexibility. Positive equity is a healthier base than in 2021, although the small cushion means this advantage depends on controlling future losses.
Negative Factors
Revenue contraction
Recent revenue contraction weakens evidence of product adoption and limits the company’s ability to absorb fixed costs. Continued declines over the next several quarters could make the path to scale and sustainable profitability increasingly difficult.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Eliminating debt reduces interest and refinancing exposure and gives the business more financial flexibility. Positive equity is a healthier base than in 2021, although the small cushion means this advantage depends on controlling future losses.
Read all positive factors
HeraMED Ltd. (HMD) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$44.03M
Dividend YieldN/A
Average Volume (3M)334.85K
Price to Earnings (P/E)―
Beta (1Y)1.21
Revenue Growth-52.35%
EPS Growth40.38%
CountryAU
Employees6
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,158,636,600
10 Day Avg. Volume354,926
30 Day Avg. Volume334,853
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)41.38
Price to Sales (P/S)131.32
P/FCF Ratio-10.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
HeraMED Ltd. Business Overview & Revenue Model
Company Description
HeraMED Ltd. (HMD) is a digital health company focused on maternal and fetal health. The company develops technology intended to support pregnancy monitoring and maternity care through connected devices and software, including solutions designed f...
HeraMED Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
21
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 102.69K | 195.77K | 225.49K | 413.19K | 215.81K | 83.68K |
| Gross Profit | 95.42K | 99.78K | 135.29K | 248.12K | -214.69K | -219.50K |
| EBITDA | -2.21M | -2.56M | -3.35M | -3.97M | -3.17M | -3.93M |
| Net Income | -2.36M | ― | -3.40M | -4.50M | -4.88M | -5.71M |
Balance Sheet | ||||||
| Total Assets | 2.15M | 994.94K | 2.78M | 2.01M | 4.19M | 4.57M |
| Cash, Cash Equivalents and Short-Term Investments | 2.03M | 914.65K | 3.13M | 723.29K | 2.64M | 3.55M |
| Total Debt | 0.00 | 282.39K | 815.96K | 209.37K | 179.53K | 3.41M |
| Total Liabilities | 234.20K | 559.96K | 1.06M | 1.55M | 1.30M | 4.13M |
| Stockholders Equity | 1.75M | 621.27K | 1.72M | 466.70K | 2.88M | -105.66K |
Cash Flow | ||||||
| Free Cash Flow | -2.18M | -2.44M | -2.98M | -5.57M | -3.20M | -3.20M |
| Operating Cash Flow | -2.18M | -2.44M | -2.98M | -5.57M | -2.52M | -3.12M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -2.05K | -690.78K | -85.43K |
| Financing Cash Flow | 3.54M | 1.27M | 6.88M | 2.96M | 2.54M | 4.88M |
HeraMED Ltd. Technical Analysis
Positive
0.04
Price Trends
0.04
Positive
0.04
Negative
0.04
Negative
Market Momentum
>-0.01
Negative
54.33
Neutral
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:HMD, the sentiment is Positive. The current price of 0.04 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and above the 200-day MA of 0.04, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 54.33 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:HMD.
HeraMED Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | AU$46.17B | 21.95 | 23.88% | 1.24% | 4.74% | 4.44% | |
61 Neutral | AU$54.93M | 213.64 | 0.93% | ― | 18.54% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$18.31M | -0.43 | -259.31% | ― | 14.85% | -1.74% | |
44 Neutral | AU$44.03M | -12.11 | -198.77% | ― | -52.35% | 40.38% | |
43 Neutral | AU$3.12M | -1.56 | -1788.57% | ― | -52.22% | 44.79% | |
41 Neutral | AU$16.24M | -4.29 | -48.97% | ― | 40.65% | 45.45% |
* Healthcare Sector Average
AU:HMD
HeraMED Ltd.
0.04
<0.01
2.86%
AU:CMP
Compumedics Limited
0.24
-0.08
-25.40%
AU:IPD
Impedimed Limited
0.01
-0.03
-65.85%
AU:UCM
Uscom Limited
0.01
<0.01
9.09%
AU:AT1
Atomo Diagnostics Ltd.
0.02
>-0.01
-15.00%
AU:RMD
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
32.09
-8.94
-21.79%
HeraMED Ltd. Corporate Events
HeraMED Narrows Half-Year Loss as Revenue Slumps but Asset Backing Improves
Aug 28, 2026
HeraMED Limited reported a sharp contraction in revenue for the half-year ended 30 June 2026, with income from ordinary activities falling 72.5% to $38,325, while its net loss narrowed 29.2% to $1.6 million compared with the prior corresponding pe...
HeraMED strengthens ASX governance with new joint company secretary
Jul 31, 2026
HeraMED Limited has announced a change in its corporate governance structure, with Stephanie Vipond stepping down as Joint Company Secretary and Nova Taylor of Bio101 Financial Advisory appointed to the role alongside existing Joint Company Secret...
HeraMED Advances U.S. Digital Pregnancy Rollout with Lee Health and Philips
Jul 31, 2026
HeraMED reported that the June 2026 quarter was dominated by progress in U.S. commercialisation, centred on its partnership with Lee Health and ongoing negotiations with Philips for an expanded commercial agreement. The company highlighted that it...
HeraMED Director’s Options Lapse, Slightly Reducing Future Equity Exposure
Jul 24, 2026
HeraMED Ltd has reported a change in director Timothy Chapman’s relevant interests following the expiry and lapse of a tranche of unlisted options. Through Inverness Capital Pty Ltd as trustee of the Match Partner Investment Account, Chapman...
HeraMED Options Expire, Simplifying ASX-Listed Medtech’s Capital Structure
Jul 24, 2026
HeraMED Ltd has confirmed the expiry of 30,428,572 listed options (HMDAZ) with an exercise price of $0.12, which lapsed unexercised on 20 July 2026. The cessation of these options reduces the company’s pool of potential dilutive securities, ...
HeraMED Pilot with Lee Health Validates Digital-First Prenatal Care Model
Jul 13, 2026
HeraMED has completed Phase 1 of its Digital Pregnancy Journey pilot with U.S. provider Lee Health, testing the HeraCARE platform within a hybrid obstetrics model that blends virtual visits and remote monitoring. The six-month feasibility study, i...
HeraMED Issues 15 Million Unquoted Options in Capital Management Move
Jun 24, 2026
HeraMED Ltd. has notified the market of the issuance of 15 million unquoted options, each exercisable at $0.06 and expiring on June 24, 2029. The options form part of a previously announced transaction and will not be quoted on the ASX, indicating...
HeraMED Issues 4 Million Unquoted Options in New Equity Class
Jun 24, 2026
HeraMED Ltd. has notified the market of the issue of 4 million unquoted options, each exercisable at $0.06 and expiring on 24 June 2029, under a new class of securities. The move modestly expands the company’s pool of equity-based instrument...
HeraMED Seeks ASX Quotation for 1.15 Million New Shares
Jun 19, 2026
HeraMED Limited has applied to the Australian Securities Exchange for quotation of 1,150,000 new ordinary fully paid shares under its ASX code HMD. The new securities, issued on 19 June 2026, arise from the exercise or conversion of existing optio...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.